Cardiovascular molecular mechanisms of disease with COVID-19

J Mol Cell Cardiol. 2020 Apr:141:107. doi: 10.1016/j.yjmcc.2020.04.010. Epub 2020 Apr 11.

Authors

Roger Foo¹, Yibin Wang², Wolfram-Hubertus Zimmermann³, Johannes Backs⁴, Dao Wen Wang⁵

Affiliations

¹ Cardiovascular Research Institute, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: foosyr@gis.a-star.edu.sg.
² Division of Molecular Medicine, Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, UCLA, United States. Electronic address: YibinWang@mednet.ucla.edu.
³ Institute of Pharmacology and Toxicology, University Medical Centre Goettingen, Germany.
⁴ Institute of Experimental Cardiology, University of Heidelberg, Germany.
⁵ Divisions of Cardiology and Internal Medicine, Wuhan Tongji Hospital, Huazhong University of Science and Technology, China.

No abstract available

MeSH terms

Acute Disease
Angiotensin-Converting Enzyme 2
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Betacoronavirus / pathogenicity*
COVID-19
Cardiovascular Diseases / diagnosis
Cardiovascular Diseases / epidemiology
Cardiovascular Diseases / etiology
Cardiovascular Diseases / genetics*
Cardiovascular System / pathology
Cardiovascular System / virology
Chronic Disease
Comorbidity
Coronavirus Infections / complications*
Coronavirus Infections / diagnosis
Coronavirus Infections / epidemiology
Coronavirus Infections / genetics
Disease Susceptibility / chemically induced
Host-Parasite Interactions / genetics
Humans
Hypertension / drug therapy
Hypertension / genetics
Pandemics
Peptidyl-Dipeptidase A / genetics
Peptidyl-Dipeptidase A / physiology
Pneumonia, Viral / complications*
Pneumonia, Viral / diagnosis
Pneumonia, Viral / epidemiology
Pneumonia, Viral / genetics
Prognosis
Publishing
Risk Factors
SARS-CoV-2
Signal Transduction / genetics

Substances

Angiotensin-Converting Enzyme Inhibitors
Peptidyl-Dipeptidase A
ACE2 protein, human
Angiotensin-Converting Enzyme 2